SL Science Holding Ltd shares exploded higher during the regular session, significantly outperforming the broader biotechnology sector. While the provided data does not contain company-specific filings or earnings announcements for the firm, the broader healthcare industry saw notable regulatory activity, including FDA approvals for new treatments and ongoing developments in RNA therapies and rare disease research. In the absence of a direct catalyst for the company, the stock's move appears to be a strong reaction to positive sentiment and momentum within the biotech space as investors digest recent regulatory updates.